KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs KSD 101 (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Adverse reactions
- Sponsors Kousai Bio
- 07 Jan 2025 New trial record